ReviewCurrent treatment options in neurology2018
Botulinum Toxin Treatment of Movement Disorders.
Review in Current treatment options in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Botulinum Toxin-A Injection in Chronic Pelvic Pain Syndrome Treatment: A Systematic Review and Pooled Meta-Analysis.Toxins · 2022Pooled it
- Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.Toxins · 2021Pooled it
- [4-Repeat Tauopathies: Progressive Supranuclear Palsy and Corticobasal Degeneration].Fortschritte der Neurologie-Psychiatrie · 2026Review
- Efficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial.Annals of medicine · 2025Article
- Review
- Quantitative analysis of the dominant external factors influencing elite speed Skaters' performance using BP neural network.Frontiers in sports and active living · 2024Article
- THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.Acta clinica Croatica · 2022Article
- European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.European child & adolescent psychiatry · 2022Review
- Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice.Toxicon: X · 2021Article
- Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy.Toxins · 2021Review
- Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.Frontiers in neurology · 2021Review
- Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment.Tremor and other hyperkinetic movements (New York, N.Y.) · 2020Review
- FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.Toxins · 2020Review
- Therapeutic properties of botulinum toxin on chronic anal fissure treatment and the patient factors role.Journal of family medicine and primary care · 2020Article
- Evidence for central antispastic effect of botulinum toxin type A.British journal of pharmacology · 2020Article
- Mechanisms of Botulinum Toxin Type A Action on Pain.Toxins · 2019Review
- Cervical Dystonia and Executive Function: A Pilot Magnetoencephalography Study.Brain sciences · 2018Article
- Botulinum Neurotoxin, an Example of Successful Translational Research.Clinical pharmacology and translational medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxins (BoNTs) are now among the most widely used therapeutic agents in clinical medicine with indications applied to the fields of movement disorders, pain disorders, and autonomic dysfunction. In this literature review, the efficacy and utility of BoNTs in the field of movement disorders are assessed using the criteria of the Guideline Development Subcommittee of the American Academy of Neurology. The literature supports a level A efficacy (established) for BoNT therapy in cervical dystonia and a level B efficacy (probably effective) for blepharospasm, hemifacial spasm, laryngeal dystonia (spasmodic dysphonia), task-specific dystonias, essential tremor, and Parkinson rest tremor. It is the view of movement disorder experts, however, that despite the level B efficacy, BoNTs should be considered treatment of first choice for blepharospasm, hemifacial spasm, laryngeal, and task-specific dystonias. The emerging data on motor and vocal tics of Tourette syndrome and oromandibular dystonias are encouraging but the current level of efficacy is U (undetermined) due to lack of published high-quality studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.